Welchol (colesevelam HCl) is now claimed to be the first and only medication approved to reduce both glucose levels (colesevelam HCl) and low density lipoprotein cholesterol levels.
Joseph Pieroni, president and CEO of Daiichi Sankyo, said: “This approval represents an important milestone for our growing US organization and underscores our continued commitment to combating cardiovascular and metabolic diseases.”